| Business Summary | | Antex
Biologics,
Inc.,
together
with
Antex
Pharma
Inc.,
a
wholly
owned
subsidiary,
is
a
biopharmaceutical
company
committed
to
developing
and
marketing
new
products
to
prevent
and
treat
infections
and
related
diseases.
The
Company
concentrates
on
the
development
of
products
for
bacterial
infections.
At
its
inception,
the
Company
was
focused
on
identifying
key
interactions
between
infectious
bacteria
and
their
host.
Early
discoveries
lead
to
the
development
of
two
novel
platform
technologies,
Antigen
Receptor
Technology
and
Nutriment
Signal
Transduction.
The
Company
also
has
developed
the
Virulence
Expression
Profiling
platform,
which
consists
of
the
application
of
genomic
expression
profiling
and
functional
genomics
to
identify
and
characterize
disease-specific
proteins
(proteomics).
These
technologies
form
the
basis
for
proprietary
vaccine
and
therapeutic
products. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Antex
Biologics,
Inc.
is
a
biopharmaceutical
company
commited
to
the
development
of
new
products
to
prevent
and
treat
infectious
diseases
and
related
disorders.
For
the
six
months
ended
6/30/01,
revenues
fell
24%
to
$120
thousand.
Net
loss
applicable
to
Common
increased
7%
to
$3.9
million.
Revenues
reflect
a
reduction
in
the
services
requested
by
SmithKline
Beecham.
Higher
loss
reflects
increased
S/G/A
costs
due
to
increased
personel. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| V. Esposito, Ph.D., 60 Chairman,
CEO | $467K | Stephen Keith, M.D., 49 Pres,
COO | -- | Jeffrey Pirone CFO,
Exec. VP | -- | W. James Jackson, P.h.D, 46 VP
of Research | -- | Alan Liss, Ph.D. VP,
Product Devel. | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|